{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:20Z","timestamp":1791924200800,"version":"4.3.4"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Turkish Society of Nephrology. F.C.F"},{"name":"Genentech Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Studies comparing all treatment options for frequently-relapsing\/steroid-dependent (FR\/SD) minimal change disease (MCD) in adults are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Medical records of 76 adults with FR\/SD MCD who were treated with corticosteroids as the first-line therapy were reviewed. Treatment options were compared for the time to relapse, change of therapy and progression (relapse on full-dose treatment).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Second-line treatments included rituximab (RTX; n\u2009=\u200913), mycophenolate mofetil (MMF; n\u2009=\u200912), calcineurin inhibitors (CNI; n\u2009=\u200926) and cyclophosphamide (CTX; n\u2009=\u200916). During the second-line treatments, 48 (71.6%) patients relapsed at median 17 (range 2\u2013100) \u2009months. The majority of relapses occurred during dose tapering or off drug. Twenty of 65 (30.8%) changed therapy after the first relapse. The median time to relapse after the second line was 66 versus 28\u2009months in RTX versus non-RTX groups (P\u2009=\u20090.170). The median time to change of treatment was 66 and 44\u2009months, respectively (P\u2009=\u20090.060). Last-line treatment options included RTX (n\u2009=\u20098), MMF (n\u2009=\u20094), CNI (n\u2009=\u20093) and CTX (n\u2009=\u20092). Seven (41.2%) patients had a relapse during the last-line treatment at median 39 (range 5\u2013112) \u2009months. The median time to relapse was 48 versus 34\u2009months in the RTX versus non-RTX groups (P\u2009=\u20090.727). One patient in the RTX group died presumably of heart failure. No major adverse event was observed. During the median follow-up of 81 (range 9\u2013355) \u2009months, no patients developed end-stage renal disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Relapse is frequent in MCD in adults. Patients treated with RTX may be less likely to require a change of therapy and more likely to come off immunosuppressive drugs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa133","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T19:09:37Z","timestamp":1589310577000},"page":"1821-1827","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease"],"prefix":"10.1093","volume":"36","author":[{"given":"Cihan","family":"Heybeli","sequence":"first","affiliation":[{"name":"Division of Nephrology, Dokuz Eyl\u00fcl University School of Medicine, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Erickson","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C","family":"Fervenza","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C","family":"Hogan","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Zand","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"key":"2021092718223183500_gfaa133-B1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021092718223183500_gfaa133-B2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021092718223183500_gfaa133-B3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrneph.2016.147","article-title":"Minimal change disease and idiopathic FSGS: manifestations of the same disease","volume":"12","author":"Maas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2021092718223183500_gfaa133-B4","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/oxfordjournals.ndt.a027136","article-title":"Long-term outcome of adult-onset minimal-change nephropathy","volume":"11","author":"Mak","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718223183500_gfaa133-B5","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ndt\/gfg134","article-title":"Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses","volume":"18","author":"Tse","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718223183500_gfaa133-B6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000046215","article-title":"Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis","volume":"21","author":"Huang","year":"2001","journal-title":"Am J Nephrol"},{"key":"2021092718223183500_gfaa133-B7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","article-title":"Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome","volume":"39","author":"Nakayama","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2021092718223183500_gfaa133-B8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/j.ajkd.2014.09.022","article-title":"Long-term outcome of biopsy-proven minimal change nephropathy in Chinese adults","volume":"65","author":"Szeto","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2021092718223183500_gfaa133-B9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.V85824","article-title":"Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults","volume":"8","author":"Tune","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"2021092718223183500_gfaa133-B10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.ajkd.2016.10.032","article-title":"The clinical course of minimal change nephrotic syndrome with onset in adulthood or late adolescence: a case series","volume":"69","author":"Maas","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2021092718223183500_gfaa133-B11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ki.1986.130","article-title":"Adult-onset minimal change nephrotic syndrome: a long-term follow-up","volume":"29","author":"Nolasco","year":"1986","journal-title":"Kidney Int"},{"key":"2021092718223183500_gfaa133-B12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ndt\/gfp422","article-title":"Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome","volume":"25","author":"Eguchi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718223183500_gfaa133-B13","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.clinthera.2012.03.008","article-title":"Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial","volume":"34","author":"Li","year":"2012","journal-title":"Clin Ther"},{"key":"2021092718223183500_gfaa133-B14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/ndt\/gfm637","article-title":"Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome","volume":"23","author":"Li","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718223183500_gfaa133-B15","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1681\/ASN.2016030342","article-title":"Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome","volume":"28","author":"Li","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021092718223183500_gfaa133-B16","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/ndt\/gft207","article-title":"Tacrolimus as rescue therapy for adult-onset refractory minimal change nephrotic syndrome with reversible acute renal failure","volume":"28","author":"Li","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718223183500_gfaa133-B17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.ajkd.2003.08.011","article-title":"Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome","volume":"42","author":"Bagga","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2021092718223183500_gfaa133-B18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2215\/CJN.01920219","article-title":"Management of adult minimal change disease","volume":"14","author":"Korbet","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021092718223183500_gfaa133-B19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.2012070734","article-title":"The treatment of minimal change disease in adults","volume":"24","author":"Hogan","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2021092718223183500_gfaa133-B20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/ndt\/gft312","article-title":"Rituximab for minimal change disease in adults: long-term follow-up","volume":"29","author":"Bruchfeld","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718223183500_gfaa133-B21","doi-asserted-by":"crossref","first-page":"28799","DOI":"10.18632\/oncotarget.25612","article-title":"Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome","volume":"9","author":"Fenoglio","year":"2018","journal-title":"Oncotarget"},{"key":"2021092718223183500_gfaa133-B22","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","article-title":"Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance","volume":"29","author":"Guitard","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718223183500_gfaa133-B23","doi-asserted-by":"crossref","first-page":"e12704","DOI":"10.1097\/MD.0000000000012704","article-title":"Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease","volume":"97","author":"Iwabuchi","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2021092718223183500_gfaa133-B24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfu022","article-title":"Sustained complete remission of steroid- and cyclophosphamide-resistant minimal-change disease with a single course of rituximab therapy","volume":"7","author":"Janardan","year":"2014","journal-title":"Clin Kidney J"},{"key":"2021092718223183500_gfaa133-B25","first-page":"16","article-title":"The efficacy of rituximab in adult frequently relapsing minimal change disease","volume":"10","author":"King","year":"2017","journal-title":"Clin Kidney J"},{"key":"2021092718223183500_gfaa133-B26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10157-015-1139-6","article-title":"Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome","volume":"20","author":"Miyabe","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"2021092718223183500_gfaa133-B27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"key":"2021092718223183500_gfaa133-B28","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int"},{"key":"2021092718223183500_gfaa133-B29","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2021092718223183500_gfaa133-B30","doi-asserted-by":"crossref","first-page":"93438","DOI":"10.18632\/oncotarget.21833","article-title":"Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"2021092718223183500_gfaa133-B31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2021092718223183500_gfaa133-B32","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","article-title":"Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults","volume":"28","author":"Takei","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2021092718223183500_gfaa133-B33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10157-011-0465-6","article-title":"Rituximab and minimal change nephrotic syndrome: a therapeutic option","volume":"15","author":"Takei","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"2021092718223183500_gfaa133-B34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.kint.2017.01.002","article-title":"A proposal for standardized grading of chronic changes in native kidney biopsy specimens","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"key":"2021092718223183500_gfaa133-B35","first-page":"139","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guidelines for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2021092718223183500_gfaa133-B36","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2021092718223183500_gfaa133-B37","doi-asserted-by":"crossref","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine (Baltimore"},{"key":"2021092718223183500_gfaa133-B38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr"},{"key":"2021092718223183500_gfaa133-B39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5414\/CN107092","article-title":"Rituximab in adult patients with immunosuppressive-dependent minimal change disease","volume":"76","author":"Hoxha","year":"2011","journal-title":"Clin Nephrol"},{"key":"2021092718223183500_gfaa133-B40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"2021092718223183500_gfaa133-B41","doi-asserted-by":"crossref","first-page":"c79","DOI":"10.1159\/000335142","article-title":"Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature","volume":"120","author":"Kisner","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2021092718223183500_gfaa133-B42","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/nep.12744","article-title":"Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease","volume":"21","author":"Papakrivopoulou","year":"2016","journal-title":"Nephrology (Carlton"},{"key":"2021092718223183500_gfaa133-B43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0272-6386(13)80001-7","article-title":"Reversible renal failure in the nephrotic syndrome","volume":"19","author":"Smith","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"2021092718223183500_gfaa133-B44","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00467-007-0617-9","article-title":"Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome","volume":"22","author":"Afzal","year":"2007","journal-title":"Pediatr Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/10\/1821\/40448976\/gfaa133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/10\/1821\/40448976\/gfaa133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:40:54Z","timestamp":1632778854000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/10\/1821\/5904444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,12]]},"published-print":{"date-parts":[[2021,9,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa133","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,9,12]]}}}